News
Published Data as of
On November 9, 2026, Eli Lilly announced that Foundayo (orforglipron) reduced sleep apnea severity in people in the phase 3 ATTAIN-OSA trial.1 In people not using positive airway pressure (PAP), Foundayo reduced apnea-hypopnea index (AHI) events by 43.8% at 52 weeks.1 The FDA approved it for weight reduction. Lilly plans to submit it to the FDA for sleep apnea by the end of 2026.1
Lilly announced positive results from ATTAIN-OSA on November 9, 2026. It is a phase 3 program in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight.1 The results were presented at the American Heart Association (AHA) Scientific Sessions 2026 and published in JAMA the same day.1
Study 1 enrolled 363 people who were unable or unwilling to use PAP. Study 2 enrolled 349 people who had used PAP for at least 3 months and kept using it.1
| Measure | Study 1, no PAP | Study 2, with PAP |
|---|---|---|
| Participants | 363 | 3491 |
| Average baseline AHI | 50.7 events per hour | 57.6 events per hour1 |
| AHI reduction at 52 weeks | 21.1 per hour (43.8%) | 18.3 per hour (27.5%)1 |
| Hypoxic burden reduction | 81.4 percent-minutes per hour (55.9%) | 75 percent-minutes per hour (45.8%)1 |
In the trial, people not using PAP saw AHI events fall by 21.1 per hour, or 43.8%, at 52 weeks.1 People using PAP saw a drop of 18.3 per hour, or 27.5%.1 Foundayo also reduced hypoxic burden in the trial, a measure of how deeply and for how long oxygen levels fall during sleep.1
The FDA approved Foundayo for weight reduction in adults with obesity, or adults with overweight and a weight-related condition. That FDA approval does not list sleep apnea.1,3 Lilly plans to submit Foundayo to the FDA for moderate-to-severe OSA in adults with obesity or overweight by the end of 2026.1
On sleep apnea, orforglipron vs tirzepatide differ in FDA status.1 The FDA has approved Zepbound, which contains tirzepatide, for moderate-to-severe OSA in adults with obesity.1
As of October 30, 2026, PepBank holds 47 studies with results where Orforglipron was given, with 340 results in total.2 By evidence class, it holds 40 publications with findings in people, 6 with findings in animals and 6 with laboratory findings in cells or tissue.2 The records list 53 registered trials that test orforglipron. They list no findings predicted by a computer model.2
The orforglipron studies hold 296 findings in people. They also hold 22 findings in animals and 22 laboratory findings in cells or tissue.2 PepBank's regulatory record shows orforglipron as approved in the US by the FDA as Foundayo in 2026.3,4
A randomized controlled trial studied people with overweight or obesity and type 2 diabetes. In that trial, each studied oral dose of orforglipron reduced body weight more than placebo.5 In another trial in people with obesity or overweight without diabetes, orforglipron lowered weight more than placebo.6
In a trial in people with diabetes at increased cardiovascular risk, orforglipron was non-inferior to insulin glargine for major adverse cardiovascular events.7 In a randomized controlled trial in people with type 2 diabetes, a studied oral dose of 12 mg lowered mean HbA1c by 1.71%.8 In a randomized controlled trial in people with early type 2 diabetes, orforglipron 3 mg by mouth, a studied dose, reduced HbA1c more than placebo.9
In trials in people, orforglipron was given by mouth. A randomized controlled trial in people studied oral doses of 6 mg, 12 mg and 36 mg once daily.5 In that trial in people with overweight or obesity and type 2 diabetes, each dose reduced body weight more than placebo. These are studied amounts, not advice.5
Lilly plans to submit Foundayo to the US FDA for moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by the end of 2026.1 Lilly shared this plan on November 9, 2026. The trial results were presented at the AHA Scientific Sessions 2026 and published in JAMA the same day.1
The FDA has approved Zepbound (tirzepatide), also made by Lilly, for moderate-to-severe obstructive sleep apnea in adults with obesity.1 The FDA approved Foundayo for weight reduction in adults with obesity, or adults with overweight and a weight-related condition. Lilly plans to submit Foundayo to the FDA for sleep apnea by the end of 2026.1
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated